Comparative Pharmacology
Head-to-head clinical analysis: DORZOLAMIDE HYDROCHLORIDE versus TRUSOPT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORZOLAMIDE HYDROCHLORIDE versus TRUSOPT.
DORZOLAMIDE HYDROCHLORIDE vs TRUSOPT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dorzolamide hydrochloride is a carbonic anhydrase II inhibitor. By inhibiting carbonic anhydrase in the ciliary processes of the eye, it reduces aqueous humor secretion, thereby lowering intraocular pressure.
Carbonic anhydrase inhibitor; decreases aqueous humor secretion by inhibiting carbonic anhydrase in the ciliary processes of the eye.
One drop of 2% solution in the affected eye(s) three times daily.
One drop of 2% solution in affected eye(s) twice daily, approximately 12 hours apart.
None Documented
None Documented
Terminal elimination half-life is approximately 4 months for red blood cell carbonic anhydrase II binding; systemic half-life of free drug is about 3-4 hours.
Terminal elimination half-life of dorzolamide in whole blood is approximately 4 months due to tight binding to carbonic anhydrase in red blood cells; however, the drug's clinical effect on intraocular pressure has a half-life of about 24 hours.
Renal: approximately 70% of a topically applied dose is excreted unchanged in urine over 120 hours; <2% fecal.
Renal excretion as unchanged drug: approximately 70% of a topically applied dose is excreted renally; the remainder is eliminated via biliary/fecal routes (30%). Following oral administration, renal excretion accounts for about 65-70%.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor